Loading...

ECTRIMS: Cancer Drug Wins in Early MS Trial

684 views

Loading...

Loading...

Transcript

The interactive transcript could not be loaded.

Loading...

Loading...

Rating is available when the video has been rented.
This feature is not available right now. Please try again later.
Published on Oct 24, 2011

AMSTERDAM -- A low-dose regimen of the leukemia drug alemtuzumab (Lemtrada) slashed annualized relapse rates in patients with newly diagnosed multiple sclerosis in a head-to-head trial against interferon-beta-1a (Rebif), a researcher reported here.

Medpage Today: http://medpagetoday.com
Online CME - Continuing medical education: http://www.medpagetoday.com/cme/
Latest medical news: http://www.medpagetoday.com/latest/

The MedPage Today app:
iOS: https://goo.gl/JKrkHq
Android: https://play.google.com/store/apps/de...

MedPage Today Youtube Channel: https://www.youtube.com/user/MedPageT...
Medpage Today on Facebook: https://www.facebook.com/MedPageToday

Loading...

to add this to Watch Later

Add to

Loading playlists...